PMID- 30670972 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 9 DP - 2018 TI - Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. PG - 1526 LID - 10.3389/fphar.2018.01526 [doi] LID - 1526 AB - Background and Objectives: Few studies have reported the drug retention rate (DRR) of biologic drugs in juvenile idiopathic arthritis (JIA), and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on systemic JIA (sJIA). This study aims to describe IL-1 inhibitors DRR and evaluate predictive factors of drug survival based on data from a real-world setting concerning sJIA. Methods: Medical records from sJIA patients treated with anakinra (ANA) and canakinumab (CAN) were retrospectively analyzed from 15 Italian tertiary referral centers. Results: Seventy seven patients were enrolled for a total of 86 treatment courses. The cumulative retention rate of the IL-1 inhibitors at 12-, 24-, 48-, and 60-months of follow-up was 79.9, 59.5, 53.5, and 53.5%, respectively, without any statistically significant differences between ANA and CAN (p = 0.056), and between patients treated in monotherapy compared to the subgroup co-administered with conventional immunosuppressors (p = 0.058). On the contrary, significant differences were found between biologic-naive patients and those previously treated with biologic drugs (p = 0.038) and when distinguishing according to adverse events (AEs) occurrence (p = 0.04). In regression analysis, patients pre-treated with other biologics (HR = 3.357 [CI: 1.341-8.406], p = 0.01) and those experiencing AEs (HR = 2.970 [CI: 1.186-7.435], p = 0.020) were associated with a higher hazard ratio of IL-1 inhibitors withdrawal. The mean treatment delay was significantly higher among patients discontinuing IL-1 inhibitors (p = 0.0002). Conclusions: Our findings suggest an excellent overall DRR for both ANA and CAN that might be further augmented by paying attention to AEs and employing these agents as first-line biologics in an early disease phase. FAU - Sota, Jurgen AU - Sota J AD - Research Center of Systemic Autoinflammatory Diseases and Behcet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy. FAU - Insalaco, Antonella AU - Insalaco A AD - Division of Rheumatology, Department of Pediatric Medicine, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Cimaz, Rolando AU - Cimaz R AD - Rheumatology Unit, Meyer Children's Hospital, University of Florence, Florence, Italy. FAU - Alessio, Maria AU - Alessio M AD - Department of Pediatrics, University of Naples Federico II, Naples, Italy. FAU - Cattalini, Marco AU - Cattalini M AD - Pediatric Clinic, University of Brescia, Brescia, Italy. FAU - Gallizzi, Romina AU - Gallizzi R AD - Department of Pediatrics, Azienda Ospedaliera Universitaria Policlinico "G. Martino" - Messina, University of Messina, Messina, Italy. FAU - Maggio, Maria Cristina AU - Maggio MC AD - Universitary Department "Pro.S.A.M.I.", University of Palermo, Palermo, Italy. FAU - Lopalco, Giuseppe AU - Lopalco G AD - Rheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - La Torre, Francesco AU - La Torre F AD - Pediatric Rheumatology Section, Pediatric Oncoematology Unit, Vito Fazzi Hospital, Lecce, Italy. FAU - Fabiani, Claudia AU - Fabiani C AD - Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy. FAU - Pardeo, Manuela AU - Pardeo M AD - Division of Rheumatology, Department of Pediatric Medicine, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Olivieri, Alma Nunzia AU - Olivieri AN AD - Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Seconda Universita degli Studi di Napoli, Naples, Italy. FAU - Sfriso, Paolo AU - Sfriso P AD - Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy. FAU - Salvarani, Carlo AU - Salvarani C AD - Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy. FAU - Gaggiano, Carla AU - Gaggiano C AD - Clinical Pediatrics, Department of Molecular Medicine and Development, University of Siena, Siena, Italy. FAU - Grosso, Salvatore AU - Grosso S AD - Clinical Pediatrics, Department of Molecular Medicine and Development, University of Siena, Siena, Italy. FAU - Bracaglia, Claudia AU - Bracaglia C AD - Division of Rheumatology, Department of Pediatric Medicine, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - De Benedetti, Fabrizio AU - De Benedetti F AD - Division of Rheumatology, Department of Pediatric Medicine, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Rigante, Donato AU - Rigante D AD - Institute of Pediatrics, Periodic Fever Research Center, Universita Cattolica Sacro Cuore, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy. FAU - Cantarini, Luca AU - Cantarini L AD - Research Center of Systemic Autoinflammatory Diseases and Behcet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy. LA - eng PT - Journal Article DEP - 20190108 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC6331484 OTO - NOTNLM OT - anakinra OT - canakinumab OT - drug retention rate OT - interleukin 1-beta OT - systemic juvenile idiopathic arthritis OT - therapy EDAT- 2019/01/24 06:00 MHDA- 2019/01/24 06:01 PMCR- 2019/01/08 CRDT- 2019/01/24 06:00 PHST- 2018/10/09 00:00 [received] PHST- 2018/12/12 00:00 [accepted] PHST- 2019/01/24 06:00 [entrez] PHST- 2019/01/24 06:00 [pubmed] PHST- 2019/01/24 06:01 [medline] PHST- 2019/01/08 00:00 [pmc-release] AID - 10.3389/fphar.2018.01526 [doi] PST - epublish SO - Front Pharmacol. 2019 Jan 8;9:1526. doi: 10.3389/fphar.2018.01526. eCollection 2018.